version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

An increased risk of cardiovascular disease, independent of conventional risk factors, is
present even at minor levels of renal impairment and is highest in patients with end-stage …

Consistent induction of donor-specific unresponsiveness in the absence of continuous
immunosuppressive therapy and toxic effects remains a difficult task in clinical organ …

Inhibitors of the mechanistic target of rapamycin (mTOR) have unique antiatherosclerotic
effects, such as depletion of plaque macrophages, induction of autophagy, and activation of …

For almost nearly a century, memory functions have been attributed only to acquired
immune cells. Lately, this paradigm has been challenged by an increasing number of …

Background: Chronic kidney disease (CKD) is an increasingly prevalent disease state met
with great morbidity and mortality primarily resulting from the high incidence of adverse …

Little is known either about either physical activity patterns, or other lifestyle-related
prevention measures in heart transplantation (HTx) recipients. The history of HTx started …

Background Medication regimen complexity (MRC) has not been characterized in detail in in
patients with end-stage renal disease (ESRD). The objective of the present study was to …

Cardiovascular events are the second most prevalent cause of non-hepatic mortality in liver
transplant recipients. The incidence of these events is projected to rise because of the …

The clinical use of cyclosporin A (CsA) has led to significant advances and achievements in
the field of transplantation and immune diseases. However, the nephrotoxicity of CsA is a …